Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

Vaccine

Volumn 33, Issue 52, 2015, Pages 7452-7461

  Richie, Thomas L ^a   Billingsley, Peter F ^a   Sim, B Kim Lee ^a   James, Eric R ^a   Chakravarty, Sumana ^a   Epstein, Judith E ^b   Lyke, Kirsten E ^c   Mordmüller, Benjamin ^d   Alonso, Pedro ^e   Duffy, Patrick E ^f   Doumbo, Ogobara K ^g   Sauerwein, Robert W ^h   Tanner, Marcel ⁱ   Abdulla, Salim ^j   Kremsner, Peter G ^d   Seder, Robert A ^f   Hoffman, Stephen L ^a  

^a SANARIA INC   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF BAMAKO   (Mali)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^j IFAKARA HEALTH INSTITUTE   (Tanzania)

more..

Author keywords

Malaria vaccine; PfSPZ Challenge; PfSPZ Vaccine; PfSPZ CVac; Plasmodium falciparum; Sporozoite

Indexed keywords

MALARIA VACCINE; SPOROZOITE VACCINE; LIVE VACCINE; VACCINE;

ABNORMAL LABORATORY RESULT; ADAPTIVE IMMUNITY; ANOPHELES STEPHENSI; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CLINICAL DEVELOPMENT PLAN; CRYOPRESERVATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER FUNCTION TEST; MALARIA; MALARIA FALCIPARUM; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN INDURATION; SPOROZOITE; ADULT; AFRICA; CLINICAL TRIAL (TOPIC); DISEASE ERADICATION; EUROPE; GENETICS; IMMUNOLOGY; MALARIA, FALCIPARUM;

ADULT; AFRICA; CLINICAL TRIALS AS TOPIC; CRYOPRESERVATION; DISEASE ERADICATION; EUROPE; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SPOROZOITES; VACCINE POTENCY; VACCINES, ATTENUATED;

EID: 84951091880     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.096     Document Type: Article

References (50)

1. Plowe C.V., Alonso P., Hoffman S.L. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 2009, 200:1646-1649.
2. Sergent E., Sergent E. Sur l'immunité dans le paludisme des oiseaux. Conservation in vitro des sporozoites de Plasmodium relictum. Immunité relative obtenue par inoculation de ces sporozoites. CR Acad Sci 1910, 151:407-409.
3. Mulligan H.W., Russell P., Mohan B.N. Active immunization of fowls against Plasmodium gallinaceum by injections of killed homologous sporozoites. J Malar Inst India 1941, 4:25-34.
4. Russell P.F., Mohan B.N. The immunization of fowls against mosquito-borne Plasmodium gallinaceum by injections of serum and of inactivated homologous sporozoites. J Exp Med 1942, 76:477-495.
5. Richards W.G.H. Active immunization of chicks against Plasmodium gallinacium by inactivated homologous sporozoites and erythrocytic parasites. Nature 1966, 212:1492-1494.
6. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
7. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973, 266:169-177.
8. Clyde D.F., McCarthy V.C., Miller R.M., Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973, 266:398-403.
9. Clyde D.F., McCarthy V.C., Miller R.M., Woodward W.E. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 1975, 24:397-401.
10. Clyde D.F. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ 1990, 68(Suppl.):9-12.
11. McCarthy V.C., Clyde D.F. Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol 1977, 41:167-171.
12. Rieckmann K.H., Carson P.E., Beaudoin R.L., Cassells J.S., Sell K.W. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1974, 68:258-259.
13. Rieckmann K.H., Beaudoin R.L., Cassells J.S., Sell D.W. Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 1979, 57(Suppl.):261-265.
14. Rieckmann K.H. Human immunization with attenuated sporozoites. Bull World Health Organ 1990, 68(Suppl.):13-16.
15. Gwadz R.W., Cochrane A.H., Nussenzweig V., Nussenzweig R.S. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 1979, 57(Suppl):165-173.
16. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
17. Egan J.E., Hoffman S.L., Haynes J.D., SadoffJ.C., Schneider I., Grau G.E., et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993, 49:166-173.
18. 3-TT and immunization with irradiated sporozoites. Bull World Health Organ 1990, 68(Suppl.):33-37.
19. Edelman R., Hoffman S.L., Davis J.R., Beier M., Sztein M.B., Losonsky G., et al. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 1993, 168:1066-1070.
20. Dame J.B., Williams J.L., McCutchan T.F., Weber J.L., Wirtz R.A., Hockmeyer W.T., et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 1984, 225(4662):593-599.
21. Ballou W.R., Hoffman S.L., Sherwood J.A., Hollingdale M.R., Neva F.A., Hockmeyer W.T., et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987, 1:1277-1281.
22. Herrington D.A., Clyde D.F., Losonsky G., Cortesia M., Murphy J.R., Davis J., et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328:257-259.
23. RTSS Clinical Trials Partnership Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015, 386:31-45.
24. Chuang I., Sedegah M., Cicatelli S., Spring M., Polhemus M., Tamminga C., et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS ONE 2013, 8:e55571.
25. Ewer K.J., O'Hara G.A., Duncan C.J., Collins K.A., Sheehy S.H., Reyes-Sandoval A., et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836.
26. Walgate R. Quest for malaria vaccine revs up, but much work remains. Bull World Health Organ 2001, 79:1002-1004.
27. Hoffman S.L., Billingsley P., James E., Richman A., Loyevsky M., Li T., et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccines 2010, 6:97-106.
28. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., James E.R., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014, 91:471-480.
29. Garcia C.R., Manzi F., Tediosi F., Hoffman S.L., James E.R. Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine 2013, 31:380-386.
30. Delemarre B.J., van der Kaay H.J. Tropical malaria contracted the natural way in the Netherlands. Ned Tijdschr Geneeskd 1979, 123:1981-1982.
31. Ponnudurai T., Leeuwenberg A.D., Meuwissen J.H. Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture. Trop Geogr Med 1981, 33:50-54.
32. Burkot T.R., Williams J.L., Schneider I. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg 1984, 78:339-341.
33. Teirlinck A.C., Roestenberg M., van de Vegte-Bolmer M., Scholzen A., Heinrichs M.J., Siebelink-Stoter R., et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis 2013, 207:656-660.
34. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science 2011, 334:475-480.
35. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
36. Roestenberg M., Bijker E.M., Sim B.K., Billingsley P.F., James E.R., Bastiaens G.J., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88:5-13.
37. Sheehy S.H., Spencer A.J., Douglas A.D., Sim B.K., Longley R.J., Edwards N.J., et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS ONE 2013, 8:e65960.
38. Hodgson S.H., Juma E.A., Salim A., Magiri C., Kimani D., Njenga D., et al. Evaluating controlled human malaria infection in kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 2014, 5:686.
39. Hodgson S.H., Juma E., Salim A., Magiri C., Njenga D., Molyneux S., et al. Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya. Malar J 2015, 14:182.
40. Gómez-Pérez G.P., Legarda A., Muñoz J., Sim B.K.L., Ballester M.R., Dobaño C., et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. Malar J 2015, 14:306.
41. Mordmüller B., Supan C., Sim K.L., Gómez-Pérez G.P., Ospina Salazar C.L., Held J., et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 2015, 14:117.
42. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361:468-477.
43. Roestenberg M., Teirlinck A.C., McCall M.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
44. Bastiaens G.J., van Meer M.P., Scholzen A., Obiero J.M., Vatanshenassan M., van Grinsven T., et al. Safety, immunogenicity and protective efficacy after intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg 2015.
45. Annoura T., van Schaijk B.C., Ploemen I.H., Sajid M., Lin J.W., Vos M.W., et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J 2014, 28:2158-2170.
46. van Schaijk B.C., Ploemen I.H., Annoura T., Vos M.W., Lander F., van Gemert G.J., et al. A genetically attenuated malaria vaccine candidate based on gene-deficient sporozoites. Elife 2014, 3.
47. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
48. Carlton J.M., Adams J.H., Silva J.C., Bidwell S.L., Lorenzi H., Caler E., et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008, 455:757-763.
49. Rehman A.M., Mann A.G., Schwabe C., Reddy M.R., Roncon Gomes I., Slotman M.A., et al. Five years of malaria control in the continental region, Equatorial Guinea. Malar J 2013, 12:154.
50. Lyke K.E., Laurens M.B., Strauss K., Adams M., Billingsley P.F., James E., et al. Optimizing intradermal administration of cryopreserved plasmodium falciparum sporozoites in controlled human malaria infection. Am J Trop Med Hyg 2015, pii: 15-0341. [Epub ahead of print]. PMID: 26416102.